Stock Analysis
- South Korea
- /
- Biotech
- /
- KOSDAQ:A196170
High Growth South Korean Tech Stocks To Watch In September 2024
Reviewed by Simply Wall St
The South Korean market has been flat in the last week and over the past year, with the financials sector down 3.1%, but earnings are forecast to grow by 29% annually. In this context, identifying high-growth tech stocks becomes crucial for investors looking to capitalize on potential opportunities in a stagnant market environment.
Top 10 High Growth Tech Companies In South Korea
Name | Revenue Growth | Earnings Growth | Growth Rating |
---|---|---|---|
Seojin SystemLtd | 33.61% | 52.05% | ★★★★★★ |
IMLtd | 21.80% | 111.43% | ★★★★★★ |
Bioneer | 23.53% | 97.58% | ★★★★★★ |
FLITTO | 32.60% | 106.82% | ★★★★★★ |
ALTEOGEN | 64.22% | 99.46% | ★★★★★★ |
NEXON Games | 31.70% | 66.31% | ★★★★★★ |
Devsisters | 25.46% | 63.02% | ★★★★★★ |
Park Systems | 23.49% | 35.59% | ★★★★★★ |
AmosenseLtd | 24.04% | 71.97% | ★★★★★★ |
UTI | 114.97% | 134.61% | ★★★★★★ |
Click here to see the full list of 49 stocks from our KRX High Growth Tech and AI Stocks screener.
Underneath we present a selection of stocks filtered out by our screen.
ALTEOGEN (KOSDAQ:A196170)
Simply Wall St Growth Rating: ★★★★★★
Overview: ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars, with a market cap of ₩17.11 billion.
Operations: The company generates revenue primarily from its biotechnology segment, which amounted to ₩90.79 million. It specializes in developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars.
ALTEOGEN's recent approval of Tergase® by the MFDS marks a significant milestone, leveraging its proprietary Hybrozyme™ Technology to deliver a recombinant hyaluronidase with over 99% purity. This positions ALTEOGEN to expand into new medical fields traditionally dominated by animal-origin products. Despite being unprofitable, the company forecasts an impressive 64.2% annual revenue growth and expects earnings to grow 99.46% per year, indicating robust future potential in South Korea's tech sector.
Lotte Energy Materials (KOSE:A020150)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Lotte Energy Materials Corporation, with a market cap of ₩1.87 trillion, produces and sells elecfoils in Korea and internationally.
Operations: Lotte Energy Materials Corporation generates revenue primarily from its Manufacturing Sector, contributing ₩768.85 billion, and the Service Sector, adding ₩218.48 billion. The company operates in both domestic and international markets.
Lotte Energy Materials has shown significant promise in South Korea's tech sector, with revenue growth forecasted at 16.3% per year, outpacing the market average of 10.8%. The company's earnings are expected to increase by an impressive 53.7% annually over the next three years, reflecting robust potential despite a recent ₩36.7B one-off loss impacting its financial results as of June 2024. Their R&D spending remains substantial, driving innovation and future competitiveness in energy materials technology.
- Click to explore a detailed breakdown of our findings in Lotte Energy Materials' health report.
Gain insights into Lotte Energy Materials' past trends and performance with our Past report.
HYBE (KOSE:A352820)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: HYBE Co., Ltd. engages in music production, publishing, and artist development and management businesses with a market cap of ₩7.49 trillion.
Operations: HYBE generates revenue primarily from its Label segment (₩1.28 trillion) and Solution segment (₩1.24 trillion), with additional income from its Platform segment (₩361.12 million). The company focuses on music production, publishing, and artist management, leveraging diverse revenue streams to support its operations.
HYBE, a notable player in South Korea's tech sector, has shown impressive earnings growth of 21.6% over the past year, outpacing the entertainment industry average of 7.3%. The company's revenue is forecast to grow at 14.1% per year, faster than the market's 10.8%, while earnings are expected to surge by an impressive 42.5% annually. Recently announcing a share repurchase program for up to 150,000 shares aimed at stabilizing stock prices highlights their strategic financial maneuvers amidst rapid growth and innovation-driven R&D investments.
- Get an in-depth perspective on HYBE's performance by reading our health report here.
Evaluate HYBE's historical performance by accessing our past performance report.
Where To Now?
- Dive into all 49 of the KRX High Growth Tech and AI Stocks we have identified here.
- Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments.
- Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors.
Looking For Alternative Opportunities?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About KOSDAQ:A196170
ALTEOGEN
A bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars.